Pci Biotech Holding Stock Net Income
| PCIB Stock | NOK 0.23 0.01 4.17% |
As of the 13th of February 2026, PCI Biotech holds the coefficient of variation of 6538.47, and Market Risk Adjusted Performance of (0.94). In respect to fundamental indicators, the technical analysis model allows you to check helpful technical drivers of PCI Biotech, as well as the relationship between them. Please check PCI Biotech Holding variance, jensen alpha, and the relationship between the standard deviation and information ratio to decide if PCI Biotech Holding is priced fairly, providing market reflects its current price of 0.23 per share.
PCI Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing PCI Biotech's valuation are provided below:PCI Biotech Holding does not today have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. PCI |
PCI Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to PCI Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of PCI Biotech.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in PCI Biotech on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding PCI Biotech Holding or generate 0.0% return on investment in PCI Biotech over 90 days. PCI Biotech is related to or competes with Pareto Bank, SpareBank, Aurskog Sparebank, 5Th Planet, Instabank ASA, and Romerike Sparebank. PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapie... More
PCI Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure PCI Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess PCI Biotech Holding upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.88 | |||
| Information Ratio | 0.0059 | |||
| Maximum Drawdown | 49.04 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 12.0 |
PCI Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for PCI Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as PCI Biotech's standard deviation. In reality, there are many statistical measures that can use PCI Biotech historical prices to predict the future PCI Biotech's volatility.| Risk Adjusted Performance | 0.0215 | |||
| Jensen Alpha | 0.1307 | |||
| Total Risk Alpha | (0.63) | |||
| Sortino Ratio | 0.0052 | |||
| Treynor Ratio | (0.95) |
PCI Biotech February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0215 | |||
| Market Risk Adjusted Performance | (0.94) | |||
| Mean Deviation | 5.12 | |||
| Semi Deviation | 6.9 | |||
| Downside Deviation | 9.88 | |||
| Coefficient Of Variation | 6538.47 | |||
| Standard Deviation | 8.61 | |||
| Variance | 74.11 | |||
| Information Ratio | 0.0059 | |||
| Jensen Alpha | 0.1307 | |||
| Total Risk Alpha | (0.63) | |||
| Sortino Ratio | 0.0052 | |||
| Treynor Ratio | (0.95) | |||
| Maximum Drawdown | 49.04 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 12.0 | |||
| Downside Variance | 97.66 | |||
| Semi Variance | 47.61 | |||
| Expected Short fall | (8.57) | |||
| Skewness | 0.2048 | |||
| Kurtosis | 7.7 |
PCI Biotech Holding Backtested Returns
As of now, PCI Stock is out of control. PCI Biotech Holding maintains Sharpe Ratio (i.e., Efficiency) of 0.0158, which implies the company had a 0.0158 % return per unit of volatility over the last 3 months. We have found twenty-eight technical indicators for PCI Biotech Holding, which you can use to evaluate the volatility of the entity. Please check PCI Biotech's coefficient of variation of 6538.47, and Market Risk Adjusted Performance of (0.94) to confirm if the risk estimate we provide is consistent with the expected return of 0.14%. PCI Biotech has a performance score of 1 on a scale of 0 to 100. The firm holds a Beta of -0.13, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning PCI Biotech are expected to decrease at a much lower rate. During the bear market, PCI Biotech is likely to outperform the market. PCI Biotech Holding now holds a risk of 9.06%. Please check PCI Biotech Holding coefficient of variation, jensen alpha, sortino ratio, as well as the relationship between the information ratio and total risk alpha , to decide if PCI Biotech Holding will be following its historical price patterns.
Auto-correlation | 0.06 |
Virtually no predictability
PCI Biotech Holding has virtually no predictability. Overlapping area represents the amount of predictability between PCI Biotech time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of PCI Biotech Holding price movement. The serial correlation of 0.06 indicates that barely 6.0% of current PCI Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.06 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, PCI Biotech Holding reported net income of (88.39 Million). This is 125.9% lower than that of the Biotechnology sector and 226.19% lower than that of the Health Care industry. The net income for all Norway stocks is 115.48% higher than that of the company.
PCI Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PCI Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PCI Biotech could also be used in its relative valuation, which is a method of valuing PCI Biotech by comparing valuation metrics of similar companies.PCI Biotech is currently under evaluation in net income category among its peers.
PCI Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (15.29) % | |||
| Current Valuation | 25.47 M | |||
| Shares Outstanding | 37.33 M | |||
| Shares Owned By Insiders | 31.97 % | |||
| Shares Owned By Institutions | 6.90 % | |||
| Price To Earning | (10.88) X | |||
| Price To Book | 1.44 X | |||
| Price To Sales | 18.74 X | |||
| Revenue | 6.27 M | |||
| Gross Profit | 6.27 M | |||
| EBITDA | (85.76 M) | |||
| Net Income | (88.39 M) | |||
| Cash And Equivalents | 116.12 M | |||
| Cash Per Share | 8.83 X | |||
| Total Debt | 1.28 M | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 16.24 X | |||
| Book Value Per Share | 1.70 X | |||
| Cash Flow From Operations | (68.31 M) | |||
| Earnings Per Share | (2.35) X | |||
| Target Price | 24.0 | |||
| Number Of Employees | 14 | |||
| Beta | 1.86 | |||
| Market Capitalization | 81.93 M | |||
| Total Asset | 135.98 M | |||
| Working Capital | 38 M | |||
| Current Asset | 48 M | |||
| Current Liabilities | 10 M | |||
| Z Score | 38.4 | |||
| Net Asset | 135.98 M |
About PCI Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PCI Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PCI Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PCI Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.